Doximity, Inc. Stock: price and insider trades · United States

In competitive terms, Doximity benefits from a strong installed base and a differentiated network effect. The company states that its network includes more than 85% of U.S. physicians across specialties and practice settings. That scale matters because the value of the platform rises with adoption, especially in healthcare, where verified identity, trust, and workflow integration are critical. Competitors include medical communication platforms, healthcare software vendors, telehealth providers, and newer AI-driven clinical reference tools. However, Doximity’s entrenched physician audience gives it a meaningful distribution advantage.

Its main products and services include secure professional communication, telehealth video, workflow tools, and clinical AI features. A notable strategic move was the acquisition of Pathway Medical, a Montreal-based startup focused on evidence-based clinical reference and medical AI. That transaction underscores Doximity’s effort to deepen its clinical utility and broaden its product suite beyond networking.

Geographically, the business remains highly concentrated in the United States, which is the company’s primary market and the core source of its user base and monetization. Although Doximity may leverage international capabilities through acquisitions or partnerships, its commercial focus is clearly domestic. Recent developments have been constructive: in its fiscal 2026 results released in May 2026, the company reported revenue growth, strong cash generation, and record usage of its workflow and AI tools. Management also highlighted new partnerships aimed at bringing Clinical AI to value-based care settings, reinforcing the view that Doximity is positioning itself as a mission-critical software layer for U.S. medical professionals.